<DOC>
	<DOCNO>NCT01513174</DOCNO>
	<brief_summary>This study gefitinib plus olaparib gefitinib combination olaparib ( AZD2281 ) versus gefitinib alone , patient Epidermal Growth Factor Receptor ( EGFR ) mutation positive advance non-small-cell lung cancer .</brief_summary>
	<brief_title>Study With Gefitinib Combination With Olaparib ( AZD2281 ) Versus Gefitinib Alone</brief_title>
	<detailed_description>This multicenter , randomize , Phase Ib/IIb , open label study evaluate efficacy tolerability gefitinib combination olaparib ( AZD2281 ) versus gefitinib alone , patient Epidermal Growth Factor Receptor ( EGFR ) mutation positive advance non-small-cell lung cancer The study split 2 part : open label Phase I dose escalation part randomize control , open label Phase II part .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Olaparib</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<criteria>1 . Patients age 18 year . 2 . Histologically confirm diagnosis nonsmallcell lung carcinoma . 3 . Stage IV disease , follow Seventh Edition American Joint Committee Cancer ( AJCC ) Cancer Staging Manual ( 27 ) . 4 . Tumor tissue available ( accord criterion specimenprocessing laboratory ) EGFR mutation assessment : include study patient present least one EGFR mutation ( exon 19 deletion L858R without T790M ) . 5 . Evidence measurable disease per Response Evaluation Criteria Solid Tumors ( RECIST ) criteria version 1.1 . 6 . ECOG score ≤ 2 . 7 . Life expectancy ≥ 3 month . 8 . For Phase II part study , patient receive previous treatment chemotherapy agent advanced disease : chemotherapy allow initial diagnosis patient limit disease patient receive adjuvant neoadjuvant treatment , long minimum 6 month pass since end adjuvant and/or neoadjuvant chemotherapy . This criterion mandatory patient include Phase I part study ( patient allow received prior line treatment advance disease ) . 9 . Patients follow hematologic value : Absolute Neutrophil Count ( ANC ) ≥1.5 x 109/L Hemoglobin ( Hb ) ≥ 10 g/dl Platelets ≥ 100 x 109/L 10 . Patients follow biochemical value : Bilirubin ≤ 1.5 mg/dL Aspartate aminotransferase ( AST ) Alanine transaminase ( ALT ) &lt; 1.5 upper limit normality Creatinine clearance ≥ 60 ml/min . 11 . Patients childbearing age either sex must use effective contraceptive method ( barrier method plus birth control method ) enter study participate study . 12 . Patients sign inform consent form inclusion study specifies clinical trial treatment entails consent analysis biological sample tumor blood . 13 . Patients must available clinical followup . 1 . Patients diagnose another neoplasm , exception cervical carcinoma insitu , treat squamous cell carcinoma superficial bladder tumor ( Ta TIS ) , malignant tumor receive curative treatment within last 5 year inclusion study . 2 . Simultaneous participation study involve investigational medicinal product , participate study le 28 day prior start study treatment . 3 . Patients HIV infection , HCV infection , coronary disease uncontrolled arrhythmia , uncontrolled cerebrovascular disease clinical condition , judgment investigator , contraindicate patient 's participation study . 4 . Past medical history interstitial lung disease ( ILD ) , druginduced interstitial disease , radiation pneumonitis require steroid treatment evidence clinically active interstitial lung disease . 5 . Preexisting idiopathic pulmonary fibrosis evidence CT scan baseline . 6 . Uncontrolled seizure . 7 . Patients consider require radiotherapy lung time study entry near future . 8 . Known suspected brain metastasis spinal cord compression , unless treat surgery and/or radiation stable without steroid treatment least 4 week prior first dose study medication . 9 . Patients unable swallow orally administer medication patient gastrointestinal disorder likely interfere absorption study medication . 10 . Patients pregnant breastfeeding . Women childbearing potential must negative pregnancy test perform within 7 day onset treatment ( Appendix 8 ) . 11 . Patients receive follow class inhibitor CYP3A4 ( see Appendix 5 guideline wash period ) : Azole antifungal Macrolide antibiotic Protease inhibitor 12 . Concomitant use know CYP3A4 inducer phenytoin , carbamazepine , rifampicin , barbiturate , St John 's Wort . 13 . Major surgery within 2 week start study treatment ; patient must recover effect major surgery . 14 . Significant weight loss ( = 10 % body weight ) 6 week inclusion study . 15 . Any condition unstable could endanger patient 's safety and/or patient 's compliance study . 16 . Substance abuse clinical , psychological social condition undermine validity inform consent protocol compliance . 17 . Patients present contraindication suspect allergy product investigation study . Tablets gefitinib contain lactose : patient rare hereditary problem galactose intolerance , Lapp lactose deficiency glucose galactose malabsorption , include trial . 18 . Contraindication steroid use . 19 . Impossibility comply treatment due cultural geographic circumstance .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>GOAL</keyword>
	<keyword>Lung</keyword>
	<keyword>Non small cell lung cancer</keyword>
	<keyword>EGFR mutation</keyword>
</DOC>